Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Randomized, Observer-Blind, Parallel, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults ≥18 Years of Age

NCT05972174 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05972174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05972174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Randomized, Observer-Blind, Parallel, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults ≥18 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 10, 2023
Completion date
July 16, 2024
Enrollment
1,504 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

influenza